Thc Biomed Intl Stock Fundamentals
THCBF Stock | USD 0 0.00 0.00% |
THC Biomed Intl fundamentals help investors to digest information that contributes to THC Biomed's financial success or failures. It also enables traders to predict the movement of THC Pink Sheet. The fundamental analysis module provides a way to measure THC Biomed's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to THC Biomed pink sheet.
THC |
THC Biomed Intl Company Return On Equity Analysis
THC Biomed's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current THC Biomed Return On Equity | -0.41 |
Most of THC Biomed's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, THC Biomed Intl is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition |
Based on the latest financial disclosure, THC Biomed Intl has a Return On Equity of -0.4132. This is 98.28% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The return on equity for all United States stocks is 33.29% higher than that of the company.
THC Biomed Intl Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining THC Biomed's current stock value. Our valuation model uses many indicators to compare THC Biomed value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across THC Biomed competition to find correlations between indicators driving THC Biomed's intrinsic value. More Info.THC Biomed Intl is rated third in return on equity category among its peers. It is rated fourth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the THC Biomed's earnings, one of the primary drivers of an investment's value.THC Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses THC Biomed's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of THC Biomed could also be used in its relative valuation, which is a method of valuing THC Biomed by comparing valuation metrics of similar companies.THC Biomed is currently under evaluation in return on equity category among its peers.
THC Fundamentals
Return On Equity | -0.41 | |||
Return On Asset | -0.15 | |||
Profit Margin | (1.56) % | |||
Operating Margin | (1.83) % | |||
Current Valuation | 6.56 M | |||
Shares Outstanding | 163.96 M | |||
Shares Owned By Insiders | 29.02 % | |||
Price To Book | 0.73 X | |||
Price To Sales | 1.37 X | |||
Revenue | 3.34 M | |||
Gross Profit | (1.03 M) | |||
EBITDA | (1.64 M) | |||
Net Income | (3.07 M) | |||
Cash And Equivalents | 1.16 M | |||
Cash Per Share | 0.01 X | |||
Total Debt | 858.43 K | |||
Debt To Equity | 0.56 % | |||
Current Ratio | 0.93 X | |||
Book Value Per Share | 0.04 X | |||
Cash Flow From Operations | (1.86 M) | |||
Earnings Per Share | (0.02) X | |||
Number Of Employees | 35 | |||
Beta | 1.12 | |||
Market Capitalization | 8.59 M | |||
Total Asset | 14.75 M | |||
Retained Earnings | (2.75 M) | |||
Working Capital | (299 K) | |||
Current Asset | 349 K | |||
Current Liabilities | 648 K | |||
Z Score | 6.0 | |||
Net Asset | 14.75 M |
About THC Biomed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze THC Biomed Intl's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of THC Biomed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of THC Biomed Intl based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.THC Biomed Intl Ltd. produces and sells medical and recreational cannabis in Canada. THC Biomed Intl Ltd. was founded in 2012 and is headquartered in Kelowna, Canada. Thc Biomed is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in THC Pink Sheet
THC Biomed financial ratios help investors to determine whether THC Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in THC with respect to the benefits of owning THC Biomed security.